Develops small-molecule drug candidates for people with genetically defined rare diseases, including pociredir for sickle cell disease.
10-K for FY2025, filed Feb 24, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$10.9MView ↗
8-K, filed Nov 12, 2026
On November 7, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, and Slate Medicines, Inc., or Slate, entered into an asset purchase agreement…View ↗
8-K, filed Aug 17, 2026
On August 16, 2026, Fulcrum Therapeutics, Inc., a Delaware corporation (“Fulcrum”) entered into an Agreement and Plan of Merger (the…View ↗
8-K, filed Jun 1, 2026
On June 1, 2026, Fulcrum Therapeutics, Inc., or the Company, announced the discontinuation of its pociredir program for the treatment of…View ↗
Portfolio focus
The older report described candidates for facioscapulohumeral muscular dystrophy and hemoglobin disorders; the latest centers on pociredir for sickle cell disease and says it will focus resources on core benign hematology programs.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 24, 2026We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in…View ↗
Competes with Bristol-Myers Squibb, Norgine, Novartis, Emmaus Life Sciences, Genetix Biotherapeutics, Vertex Pharmaceuticals, Pfizer, Novo Nordisk, GSK, Cellarity, Agios Pharmaceuticals, Sanofi, and Beam Therapeutics
10-K for FY2025, filed Feb 24, 2026Several approved therapies for SCD are intended to reduce VOCs or other complications of SCD. The five drug treatments approved in the…View ↗
Loading...